A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP

HIV Infections Clinical Trial

— PrEPVacc  

Official title:

A Phase IIb Three-arm, Two-stage HIV Prophylactic Vaccine Trial With a Second Randomisation to Compare TAF/FTC to TDF/FTC as Pre-exposure Prophylaxis

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04066881
• Other study ID #: RGPK190803
• Status: Enrolling by invitation
• Phase: Phase 2
• Start date: December 15, 2020
• Est. completion date: December 31, 2024

Study information

• Verified date: October 2023
• Source: MRC/UVRI and LSHTM Uganda Research Unit
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This international, multi-centre, double-blind vaccine study is a three-arm prospective 1:1:1 randomisation comparing each of two experimental combination vaccine regimens i.e. DNA/AIDSVAX (weeks 0,4,24,48) and DNA/CN54gp140 (weeks 0,4) + MVA/CN54gp140 (weeks 24,48) with placebo control. There will be a concurrent open-label 1:1 randomisation to compare daily TAF/FTC (week 0-26) to daily TDF/FTC (weeks 0-26) as pre-exposure prophylaxis. The study aims to randomise up to 1668 eligible adults (18-40 years) through collaborating clinical research centres in 4 countries (Mozambique; South Africa; Tanzania; and Uganda). Each participant will be followed for a minimum of 74 weeks after enrolment. The trial is designed to detect a reduction in HIV incidence that has public health relevance sufficient to justify implementation of the combination vaccine regimen. In light of the high level of effectiveness demonstrated in the PrEP trials (up to 86% reduction in HIV), this trial is powered to detect a protective vaccine efficacy of 70% at the final analysis. The PrEP component will determine whether the effectiveness of TAF/FTC is unacceptably lower than the effectiveness of TDF/FTC.

Description:

This international, multi-centre, double-blind vaccine study will be a three-arm prospective 1:1:1 randomisation comparing each of two experimental combination vaccine regimens with placebo control. Pre-screening for risk and HIV status will take place as part of a Registration Cohort which will precede and continue in parallel to the PrEPVacc trial enrolments. This will give HIV negative volunteers time to learn about the PrEPVacc trial and facilitate timely enrolment. Clinical screening for the vaccine trial will take place during the 8 weeks prior to randomisation from local communities in Mozambique, South Africa, Tanzania and Uganda where the clinical research centres are located. Eligible participants who are HIV-uninfected adults aged 18-40 years at high risk of HIV infection will be enrolled at week 0 and randomised to one of three vaccine arms: 1. Vaccine group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48) 2. Vaccine group B: DNA-HIV-PT123 and CN54gp140 in MPLA-L (wks 0,4), then MVA-CMDR and CN54gp140 in MPLA-L (wks 24,48) 3. Vaccine group C: Saline Placebo (wks 0,4,24,48) There will be a concurrent open-label 1:1 randomisation to one of two PrEP regimens: 1. Control PrEP: Daily TDF/FTC (week 0-26) 2. Experimental PrEP: Daily TAF/FTC (week 0-26) Participants will be randomised at each clinical centre through web randomisation after entering the quantifiable eligibility criteria. Randomisation will be stratified by centre and by gender for vaccines and for PrEP. Clinic staff and participants will be blind to allocation of active or placebo vaccines, but the pharmacist preparing the vaccines will know. As the volume of gp140 in MPLA-L is 0.4ml and given at the same timepoints as products with a volume of 1ml, clinic staff will be able to identify participants allocated to the CN54gp140 in MPLA-L or matched placebo. Clinic staff and participants will know which PrEP agent each participant is allocated to. Participants will continue to receive study PrEP through to week 26 after which access to PrEP will revert to local supply of generic drug. The target accrual is around 1668 HIV uninfected adults, but this is an endpoint driven multi-arm, multi-stage (MAMS) trial design, and therefore the target may be adjusted following a recommendation from the IDMC. In addition, participants who do not complete the third immunisation will be replaced whilst this is feasible. Participants will be followed up for a minimum of 74 weeks after enrolment. The primary efficacy outcome measure for the vaccine analysis is HIV acquisition by a participant who completed three immunisations and was HIV negative at week 26. The primary efficacy outcome for the PrEP analysis is HIV acquisition at or before week 26 by a participant who was HIV negative at enrolment. The primary safety outcome for both analyses is a clinical decision to discontinue the vaccine or PrEP regimen for an adverse event that is considered related to product. This trial is designed to detect a reduction in HIV incidence that has public health relevance sufficient to justify implementation of the combination vaccine regimen. In light of the high level of effectiveness demonstrated in the PrEP trials (up to 86% reduction in HIV), this trial is powered to detect a protective vaccine efficacy of 70% at the final analysis. The PrEP component of the trial aims to show the effectiveness of TAF/FTC is not unacceptably lower than the effectiveness of TDF/FTC, assessed from the observed lower confidence limit for the Averted Infections Ratio (AIR). The Independent Data Monitoring Committee will review an interim analysis of vaccine efficacy in order to determine whether each active vaccine arm has demonstrated sufficient efficacy to warrant further investigation. This analysis will only consider new infections arising after the week 26 visit and only those in individuals who have completed the first three immunisations. The analysis will take place after approximately 7 of these infections have occurred in the placebo group. The investigators will not be informed of the timing of the interim analysis, unless there is a recommendation to modify the protocol. The PrEP analysis will consider new infections up to the week 26 visit in individuals who were HIV negative at enrolment.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 1668
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion criteria

1. HIV uninfected adults aged between 18 and 40 years old on the day of screening

2. Willing and able to provide informed consent prior to participation

3. Willing and able to comply with the visit schedule and provide blood, urine and other samples at the required time points

4. Home address accessible for visiting and intending to remain within the recruitment area for at least 82 weeks from screening

5. Likely to be at risk from exposure to HIV during follow up

6. Willing to undergo HIV testing, receive HIV test results and risk reduction counselling which includes promotion of PrEP and condoms

7. If female, of child-bearing age and not sterilised, willing to use a highly effective method of contraception from screening until 18 weeks after the last injection

8. If male and not sterilised, willing to avoid impregnating female partners from screening until 18 weeks after the last injection Exclusion criteria

1. HIV infection or indeterminate HIV result at screening or enrolment

2. Hepatitis B surface antigen positive

3. If female, currently pregnant (evidence from positive serum or urine pregnancy test), or lactating

4. Participating in another biomedical research study or in receipt of a live vaccine within 30 days prior to randomisation

5. Participation in a previous HIV vaccine or HIV immunotherapy trial

6. Receiving blood products or immunoglobulins within 12 weeks of screening

7. Known hypersensitivity to any component of the vaccine formulations used in this trial or history of severe or multiple allergies to vaccines, drugs or pharmaceutical agents

8. Presence of a systemic disease at the time of randomisation or history of chronic illness that in the opinion of the investigator may compromise the participant's safety, preclude vaccination or compromise an immune response to vaccine

9. Abnormalities in routine laboratory parameters (Hb, creatinine, AST/ALT, alkaline phosphatase, total Bilirubin and glucose) of Grade 2 and above using the DAIDS toxicity table, version 2.1 July 2017 or estimated glomerular filtration rate less than 50ml/min

Related Conditions & MeSH terms

• HIV Infections

Intervention

Biological:
• Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)
DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef. AIDSVAX® B/E is a bivalent HIV gp120 glycoprotein encompassing both subtype B (MN) and subtype E (A244) proteins that are adsorbed onto 600mcg of aluminum hydroxide gel suspension as adjuvant.
• Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)
DNA-HIV-PT123 (see above) CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity. MVA-CMDR (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is a non-replicating, highly attenuated strain of Vaccina virus that has been genetically engineered to express the HIV-1 genes envgp160 CM235 Subtype E and gag and pol CM240 Subtype A (integrase-deleted and reverse transcriptase non-functional).
• Vaccine Group C: Saline placebo (weeks 0,4,24,48)
Sodium Chloride (NaCl) for injection, 0.9%

Drug:
• Control PrEP:TDF/FTC once daily (weeks 0-26)
Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
• Experimental PrEP:TAF/FTC once daily (weeks 0-26)
Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.

Locations

Country	Name	City	State
Uganda	MRC/UVRI and LSHTM Uganda Research Unit	Entebbe

Sponsors (15)

Lead Sponsor

Collaborator

MRC/UVRI and LSHTM Uganda Research Unit

Centre Hospitalier Universitaire Vaudois, CONRAD, EuroVacc Foundation, Gilead Sciences, Imperial College London, Instituto Nacional de Saúde, Mozambique, International AIDS Vaccine Initiative, Karolinska Institutet, King's College London, Ludwig-Maximilians - University of Munich, Medical Research Council, South Africa, Muhimbili University of Health and Allied Sciences, National Institute for Medical Research, Tanzania, University College, London

Country where clinical trial is conducted

Uganda, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incident HIV infection	HIV acquisition by a participant who completed three immunisations and was HIV negative at week 26.	after week 26
Primary	Incident HIV infection	HIV acquisition at or before week 26 by a participant who was HIV negative at enrolment	week 0-26
Primary	A clinical decision to discontinue the vaccine regimen for an adverse event that is considered related to product	A clinical decision to discontinue the vaccine regimen for an adverse event that is considered related to product	week 0-48
Primary	A clinical decision to discontinue PrEP regimen for an adverse event that is considered related to product	A clinical decision to discontinue PrEP regimen for an adverse event that is considered related to product	week 0-26
Secondary	Grade 3 and worse solicited clinical and laboratory adverse events	Grade 3 and worse solicited clinical and laboratory adverse events	week 0-74
Secondary	Discontinuation or interruption of vaccine regimen	A clinical decision to discontinue or interrupt the vaccine regimen for an adverse event that is considered related to product	week 0-74
Secondary	Discontinuation or interruption of PrEP	A clinical decision to discontinue or interrupt the PrEP regimen for an adverse event that is considered related to product	week 0-26
Secondary	Grade 3 and worse solicited clinical and laboratory adverse events	Grade 3 and worse solicited clinical and laboratory adverse events	within 7 days of receiving vaccine injection
Secondary	Serious adverse events	Serious adverse events	week 0-74
Secondary	Other clinical and laboratory adverse events	Other clinical and laboratory adverse events	week 0-74
Secondary	Binding antibodies	Binding antibodies to Cn54gp140 and AIDSVAX® B/E gp120	week 0-74
Secondary	Resistance mutations to tenofovir and emtricitabine	Genotypic resistance at HIV seroconversion, focussing on the mutations selected by tenofovir and emtricitabine (codons 65, 70, 184 in reverse transcriptase)	week 0-74
Secondary	Number of PrEP pills missed	Adherence to PrEP assessed by self-report	week 0-26
Secondary	Tenofovir level in urine	Adherence to PrEP assessed by results of point of care urine tests	week 0-26
Secondary	Tenofovir level in red blood cells	Adherence assessed by TFV DP levels measured on DBS in red blood cells	week 0-26
Secondary	Number of PrEP Pills dispensed	Adherence assessed by total number of PrEP pills dispensed	week 0-26